LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Accueil・Liste d'Actions・Denali Therapeutics Inc

Denali Therapeutics Inc

Fermé

SecteurSoins de santé

19.7 -3.62

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

19.16

Max

20.37

Chiffres clés
By Trading Economics
Revenu	-1.6M -129M
Employés	503
EBITDA	8.9M -125M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+94.27% upside

Dividendes
By Dow Jones
Prochains Résultats	11 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-295M 3B
Ouverture précédente	23.32
Clôture précédente	19.7

Sentiment de l'Actualité

By Acuity

10%

90%

9 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

13.355 / 16.44 Support & Résistance

Denali Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 mai 2026, 23:41 UTC

Résultats

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mai 2026, 21:40 UTC

Résultats

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mai 2026, 23:13 UTC

Résultats

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mai 2026, 23:13 UTC

Résultats

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mai 2026, 23:12 UTC

Résultats

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mai 2026, 23:11 UTC

Résultats

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mai 2026, 23:11 UTC

Résultats

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:11 UTC

Résultats

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mai 2026, 23:11 UTC

Résultats

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mai 2026, 23:11 UTC

Résultats

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mai 2026, 23:11 UTC

Résultats

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:07 UTC

Résultats

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mai 2026, 23:06 UTC

Résultats

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mai 2026, 23:06 UTC

Résultats

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mai 2026, 23:05 UTC

Résultats

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mai 2026, 23:04 UTC

Résultats

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mai 2026, 22:50 UTC

Résultats

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mai 2026, 22:11 UTC

Résultats

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mai 2026, 22:11 UTC

Résultats

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mai 2026, 21:58 UTC

Résultats

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:47 UTC

Market Talk

Résultats

Costco Posts 13% Sales Growth in April -- Market Talk

6 mai 2026, 21:46 UTC

Résultats

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mai 2026, 21:40 UTC

Résultats

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mai 2026, 21:32 UTC

Actions en Tendance

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mai 2026, 21:29 UTC

Résultats

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparaison

Variation de prix

Denali Therapeutics Inc prévision

Objectif de Prix

By TipRanks

94.27% hausse

Prévisions sur 12 Mois

Moyen 36.27 USD 94.27%

Haut 42 USD

Bas 30 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

13.355 / 16.44Support & Résistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

9 / 347Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.